Experimental drug combo aims to make inoperable stomach cancers removable

NCT ID NCT07709767

Not yet recruiting Disease control Sponsor: Tang-Du Hospital Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests whether adding an experimental drug called retlirafusp alfa to standard chemotherapy can shrink advanced stomach or gastroesophageal junction cancers enough to allow complete surgical removal. Participants receive the drug combination before surgery, and those whose tumors respond well will undergo radical surgery. The main goal is to see how many patients achieve a clean surgical margin (R0 resection).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: retlirafusp alfa plus CAPOX chemotherapy (capecitabine and oxaliplatin)
What this could lead to: If successful, this approach could help more patients with advanced stomach cancer become eligible for surgery that completely removes the tumor.
What could go wrong: This is a small, early-phase study with only 21 participants, so results may not apply broadly. The combination therapy may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC ADENOCARCINOMA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.